dalteparin has been researched along with epirubicin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altinbas, M; Cetin, M; Coskun, HS; Er, O; Eser, B; Ozkan, M; Soyuer, S; Unal, A | 1 |
| Blaskó, G; Nagy, Z; Turcsik, V | 1 |
| Nordenhem, A; Norrby, K | 1 |
2 trial(s) available for dalteparin and epirubicin
| Article | Year |
|---|---|
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dalteparin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Heparin, Low-Molecular-Weight; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome; Vincristine | 2004 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Nadroparin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Analysis; Time Factors | 2009 |
1 other study(ies) available for dalteparin and epirubicin
| Article | Year |
|---|---|
Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Anticoagulants; Body Weight; Dalteparin; Epirubicin; Immunohistochemistry; Infusions, Subcutaneous; Male; Mesenteric Arteries; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Vascular Endothelial Growth Factor A | 2010 |